Y-mAbs(US:YMAB) ZACKS·2025-03-04 13:45Core Viewpoint - Y-mAbs Therapeutics, Inc. reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, marking a 15.38% earnings surprise [1][2] Financial Performance - The company posted revenues of $26.5 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.40%, compared to revenues of $23.36 million a year ago [2] - Over the last four quarters, Y-mAbs has not surpassed consensus EPS estimates and has consistently missed revenue estimates [2][3] Stock Performance - Y-mAbs shares have declined approximately 33.7% since the beginning of the year, contrasting with the S&P 500's decline of only 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $24.61 million, and for the current fiscal year, it is -$0.59 on revenues of $104.97 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Y-mAbs belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]